The platform leverages the company’s Eudragit functional coatings, aiming to optimise the release profile of oral drug products
Evonik has launched the Eudracap platform of capsules, designed to help the pharmaceutical industry accelerate speed to market for complex oral drug products in early development stages. The enteric coated pre-locked capsule gives optimises gastric resistance, boosts intestinal absorption and enhances bioavailability, the company claims.
“With the help of Eudracap, we expect strong growth within our innovation growth field Healthcare Solutions,” said Paul Spencer, Head of Product line Drug Delivery & Medical Device Solutions at Evonik’s Health Care business line. “Eudracap will foster our position as a fully integrated CDMO along the entire pharmaceutical value chain.”
The platform leverages the company’s Eudragit functional coatings, aiming to optimise the release profile of oral drug products. The coated HPMC (hydroxypropyl methyl cellulose) capsules are designed to protect sensitive active pharmaceutical ingredients from moisture and gastric acid.
There is a recent emphasis on oral drugs using mRNA or targeting the microbiome, Evonik says. This has created demand in the pharmaceutical industry for ways to increase the number of sensitive molecules in drug product portfolios.
“Eudracap is our answer to many of the challenges innovators in the pharmaceutical industry are facing when pioneering oral drug products,” said Dr Axel Schröder, head of Global Business Segment Oral Drug Delivery Solutions at Evonik Health Care.
The line provides CDMO services for customer requirements including a range of sizes, colors, and customised release profiles.
“We can help reduce risk and get the finished dosage form in the hands of our customers for clinical and commercial use as fast as possible,” said Dr Bettina Hölzer, Senior Project Manager Strategic Marketing Oral Drug Delivery Solutions at Evonik Health Care. With this platform, customers can t into Evonik’s expertise across application areas such as colonic delivery, microbiome delivery, personalized dosage forms and bioavailability enhancement.
In 2020, Evonik began marketing Eudratec Fasteric, an advanced oral drug delivery technology that provides enteric protection followed by rapid, homogeneous release targeting the upper small intestine.